摘要
目的探讨阿帕替尼联合白蛋白结合型紫杉醇治疗食管癌术后远处转移患者的疗效及不良反应。方法回顾性分析泰安市肿瘤防治院2019年3月—2022年1月收治的70例食管癌术后远处转移患者,根据治疗方案不同分为治疗组(注射用紫杉醇白蛋白结合型联合阿帕替尼治疗)35例,对照组(单用注射用紫杉醇白蛋白结合型化疗)35例,观察两组的近期疗效、无病进展期以及不良反应。结果治疗组客观缓解率(ORR)、疾病控制率(DCR)高于对照组,差异有统计学意义(P<0.05);治疗组中位无进展生存期(PFS)较对照组长,差异有统计学意义(P<0.05);治疗过程中两组均出现白细胞下降、血小板下降、肝功异常、胃肠道反应等不良反应,组间比较差异无统计学意义(P>0.05);治疗组在口服阿帕替尼期间发生高血压、蛋白尿、手足综合征症状均能耐受,对症处理后均能缓解,两组比较差异无统计学意义(P>0.05)。结论阿帕替尼联合白蛋白结合型紫杉醇治疗食管癌术后远处转移的患者,局部控制率好,无病进展期延长,不良反应少。
Objective To investigate the effi cacy and adverse eff ects of apatinib combined with albumin-bound paclitaxel in the treatment of patients with distant metastases after esophageal cancer.Methods A retrospective analysis was performed on 70 patients with distant metastasis after esophageal cancer admitted to Tai'an Cancer Hospital from March 2019 to January 2022,according to the treatment plan,35 cases were divided into treatment group(paclitaxel albumin-binding combination with apatinib for injection)and 35 cases in the control group(paclitaxel albumin-binding chemotherapy for single-agent injection),and the short-term efficacy,disease-free progression,and adverse reactions of the two groups were observed.Results The diff erence was statistically signifi cant compared with the objective response rate(ORR)and the disease control rate(DCR)between the treatment group and the control group(P<0.05).There were statistical differences between the median PFS of the treatment group and the control group(P<0.05).There were no signifi cant diff erences in white blood cell decrease,platelet decrease,abnormal liver function,and gastrointestinal reactions during treatment(P>0.05),The symptoms of hypertension,proteinuria,and hand-foot syndrome in the treatment group were tolerated during oral apatinib,and alleviated after symptomatic treatment,and there was no signifi cant diff erence between the two groups(P>0.05).Conclusion Apatinib combined with albumin-bound paclitaxel in patients with distant metastasis after esophageal cancer surgery has good local control rate,prolonged disease-free progression,and less adverse reactions.
作者
李梁
亓迪
李玉
袁磊
王娥
朱俊迪
耿晓萌
李文文
任伟
LI Liang;QI Di;LI Yu;YUAN Lei;WANG E;ZHU Jun-di;GENG Xiao-meng;LI Wen-wen;REN Wei(Department of Radiotherapy,Tai'an Cancer Prevention and Treatment Hospital,Tai'an Shandong 271000,China;Department of Pediatrics,Tai'an Central Hospital,Tai'an Shandong 271000,China;Department of Disease Control and Prevention,906th Hospital of PLA,Ningbo Zhejiang 315000,China)
出处
《中华养生保健》
2023年第15期16-19,共4页
CHINESE HEALTH CARE
关键词
食管癌
阿帕替尼
紫杉醇
esophageal cancer
apatinib
paclitaxel
